Carles Escriu's Avatar

Carles Escriu

@carlesescriu.bsky.social

Thoracic Medical Oncologist and Honorary Clinical Lecturer. Liverpool, England, UK.

40 Followers  |  64 Following  |  3 Posts  |  Joined: 05.02.2025  |  1.4257

Latest posts by carlesescriu.bsky.social on Bluesky

Post image

The job of a doctor is not, necessarily, to be kind or popular or fluffy or liked.

It is to do and to say the right thing for your patients.

However difficult it may be to do so.

However tough you may find it.

Many institutions pretend otherwise, including the GMC.

Here's why they're wrong 🧡

18.05.2025 16:15 β€” πŸ‘ 162    πŸ” 39    πŸ’¬ 9    πŸ“Œ 7

@ajuntamentbcn.bsky.social

28.04.2025 05:43 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

Easy access to diagnostic investigations in primary care is likely to diagnose cancer earlier and prolong patient's lives.

Optimal management of comorbidities is also likely to facilitate access to radical cancer therapies.

NHS cancer funding needs to take the entire picture into account.

08.03.2025 08:54 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image Post image

Graham Warren on smoking cessation in lung cancer pts.

Extraordinary data:

πŸ”Ί $3.4bn cost of failed treatment if don’t quit
πŸ”Ί ⬇️ 45% mortality if quit
πŸ”ΊLess frequent reminders more effective than more
πŸ”Ί Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit

Sensational talk 🀯

05.03.2025 09:23 β€” πŸ‘ 9    πŸ” 7    πŸ’¬ 0    πŸ“Œ 0

SCLC was indeed the star at #BTOG25. Looking forward to the benefit (and challenges) of novel therapeutic strategies.

Translational studies to aid patient selection will now be more needed than ever.

05.03.2025 12:40 β€” πŸ‘ 4    πŸ” 0    πŸ’¬ 0    πŸ“Œ 1
Preview
First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, showed significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patie...

New 5-year data from the CROWN trial in Asian ALK+ #lungcancer: Lorlatinib continues to show longer progression-free survival than crizotinib, with 63% progression-free at 5 years vs. 7% with crizotinib. Strong intracranial response rates too. www.jto.org/article/S155... #LCSM

02.03.2025 10:32 β€” πŸ‘ 5    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0
Post image

The 2nd part of the Therapeutics Symposium at #BTOG25 Annual Conference is chaired by
@carlesescriu.bsky.social and @tnewsomdavis.bsky.social, covering β€œRefining Patient Selection”.
btog.org/23rd-btog-an...

18.02.2025 15:51 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

@carlesescriu is following 19 prominent accounts